Polymorphisms of paraoxonase genes and low-density lipoprotein lipid peroxidation

Lancet

Volumn 353, Issue 9151, 1999, Pages 468-469

  Mackness, Bharti ^a   Durrington, Paul N ^b   Mackness, Michael I ^b  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME POLYMORPHISM; HUMAN; ISCHEMIC HEART DISEASE; LIPID PEROXIDATION; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0033528205     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)05105-8     Document Type: Article

References (5)

1. Mackness M.I., Abbott C.A., Arrol S., Durrington P.N. The role of high density and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J. 294:1993;829-835.
2. Mackness B., Mackness M.I., Arrol S., Turkie W., Durrington P.N. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett. 423:1998;57-60.
3. Aviram M., Billecke S., Sorenson R.et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities. Arterioscler Thromb Vasc Biol. 18:1998;1617-1624.
4. Mackness B., Durrington P.N., Mackness M.I. Human serum paraoxonase. Gen Pharmacol. 31:1998;329-336.
5. Sanghera D.K., Aston C.E., Saha N., Kamboh M.I. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with risk of coronary heart disease. Am J Human Genet. 62:1998;36-44.